The Foundation for Sarcoidosis Research and American Thoracic Society Announce Dr. Mark Mallozzi as the New FSR/ATS Partner Grant Awardee
CHICAGO, June 05, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS) are pleased to announce that Mark Mallozzi, MD, MPH has been selected to receive the 2025 ATS/FSR Partner Grant, awarded to support innovative research in sarcoidosis and advance patient care.
The FSR/ATS Partner Grant, a cornerstone of both organizations' commitment to fostering early-career investigators, provides $100,000 in funding—$50,000 per year over two years—to support groundbreaking research projects that have the potential to significantly impact the understanding and treatment of sarcoidosis. Since 2005, this partnership has funded over $1 million in sarcoidosis research, catalyzing further advancements in the field.
'Dr. Mallozzi's grant will provide the scientific community with valuable insight into the environmental causes of sarcoidosis,' said Mary McGowan, President and CEO of FSR. 'We are pleased to partner with the American Thoracic Society to support dedicated investigators like Dr. Mallozzi who are committed to increasing the understanding of this complex disease.'This year's awardee, Mark Mallozzi, MD, MPH from National Jewish Health was selected for his project titled 'Association of PM2.5 exposure with sarcoidosis outcomes at baseline and longitudinal follow-up'. This study will look at a possible link between air pollution and sarcoidosis.
'This grant will be essential in advancing my career as a physician-scientist focusing on sarcoidosis and environmental exposures,' said Mark Mallozzi MD. 'Through this project, I will advance my research skills and scientific writing and presenting, build a network of collaborators, and produce foundational data for future projects. This project is a meaningful step in my goal of securing a National Institutes of Health Research Career Development Award (K).'
'We are immensely grateful to our non-profit partners for their continued collaboration and for their support of the young researchers who are contributing to greatly-improved outcomes for patients across the spectrum of respiratory health,' said Kamran Atabai, MD, chair of the ATS Scientific Grant Review Committee.
For more information about the FSR research funding programs, visit https://www.stopsarcoidosis.org/fsr-grants.
About SarcoidosisSarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States.
About the Foundation for Sarcoidosis ResearchThe Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: www.stopsarcoidosis.org.
About the ATS FoundationSince its inception, the ATS Foundation Research Program has awarded more than $24 million in early career researchers has leveraged well over $880 million in NIH funding and breakthroughs in respiratory medicine. You can learn more about our most recent awardees here.
Media Contact:Cathi Davis, Director of Communications and MarketingFoundation for Sarcoidosis Research312-341-0500cathi@stopsarcoidosis.org
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/46aa564f-1606-4532-bb78-57eb14158704
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
The Foundation for Sarcoidosis Research and American Thoracic Society Announce Dr. Mark Mallozzi as the New FSR/ATS Partner Grant Awardee
CHICAGO, June 05, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS) are pleased to announce that Mark Mallozzi, MD, MPH has been selected to receive the 2025 ATS/FSR Partner Grant, awarded to support innovative research in sarcoidosis and advance patient care. The FSR/ATS Partner Grant, a cornerstone of both organizations' commitment to fostering early-career investigators, provides $100,000 in funding—$50,000 per year over two years—to support groundbreaking research projects that have the potential to significantly impact the understanding and treatment of sarcoidosis. Since 2005, this partnership has funded over $1 million in sarcoidosis research, catalyzing further advancements in the field. 'Dr. Mallozzi's grant will provide the scientific community with valuable insight into the environmental causes of sarcoidosis,' said Mary McGowan, President and CEO of FSR. 'We are pleased to partner with the American Thoracic Society to support dedicated investigators like Dr. Mallozzi who are committed to increasing the understanding of this complex disease.'This year's awardee, Mark Mallozzi, MD, MPH from National Jewish Health was selected for his project titled 'Association of PM2.5 exposure with sarcoidosis outcomes at baseline and longitudinal follow-up'. This study will look at a possible link between air pollution and sarcoidosis. 'This grant will be essential in advancing my career as a physician-scientist focusing on sarcoidosis and environmental exposures,' said Mark Mallozzi MD. 'Through this project, I will advance my research skills and scientific writing and presenting, build a network of collaborators, and produce foundational data for future projects. This project is a meaningful step in my goal of securing a National Institutes of Health Research Career Development Award (K).' 'We are immensely grateful to our non-profit partners for their continued collaboration and for their support of the young researchers who are contributing to greatly-improved outcomes for patients across the spectrum of respiratory health,' said Kamran Atabai, MD, chair of the ATS Scientific Grant Review Committee. For more information about the FSR research funding programs, visit About SarcoidosisSarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States. About the Foundation for Sarcoidosis ResearchThe Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: About the ATS FoundationSince its inception, the ATS Foundation Research Program has awarded more than $24 million in early career researchers has leveraged well over $880 million in NIH funding and breakthroughs in respiratory medicine. You can learn more about our most recent awardees here. Media Contact:Cathi Davis, Director of Communications and MarketingFoundation for Sarcoidosis Research312-341-0500cathi@ A photo accompanying this announcement is available at
Yahoo
2 days ago
- Yahoo
Foundation for Sarcoidosis Research Announces 2025 Global Virtual Sarcoidosis Summit – United for Progress: A New Chapter in Sarcoidosis
CHICAGO, June 04, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving patient support, is proud to announce the 2025 FSR Global Virtual Sarcoidosis Summit, taking place Saturday, June 28, through Sunday, June 29, 2025. This year's theme, "United for Progress: A New Chapter in Sarcoidosis," emphasizes connection, education, and empowerment for individuals impacted by sarcoidosis around the world. Now in its fourth year, the FSR Global Virtual Sarcoidosis Summit is the world's largest online sarcoidosis event, bringing together patients, caregivers, clinicians, and researchers for two days of expert-led sessions, interactive discussion forums, and community-building opportunities. The summit offers critical tools and knowledge to help attendees take control of their health, better understand the disease, and find a global support network. 'The 2025 Summit is more than just an event — it's a powerful opportunity to unite the global sarcoidosis community around shared learning, personal empowerment, and collective progress,' said Mary McGowan, FSR President and CEO. 'With sessions designed for patients, caregivers, and clinicians alike, the summit aims to break down barriers to care and ensure that no one has to face sarcoidosis alone.' Attendees will explore over 20 live and on-demand sessions led by world-renowned sarcoidosis experts, covering critical and rarely discussed topics including: Sarcoidosis 101: From Diagnosis to Management Environmental Triggers in Sarcoidosis Genetics and Familial Connections Intimacy and Sarcoidosis Fatigue, Brain Fog, and Invisible Symptoms What's Sarcoidosis and What's Not? Understanding Organ Involvement, Monitoring, and Shared Decisions Ask the Sarcoidosis Experts Rare Manifestations of Sarcoidosis Nutrition, Lifestyle, and Mental Health Strategies Navigating Insurance and Access to Care FSR is honored to welcome actress and sarcoidosis advocate, Jeryl Prescott Gallien, as the 2025 Summit keynote speaker. Best known for roles in Star Wars, The Walking Dead, Swamp Thing, and All the Queen's Men, Jeryl brings a powerful voice as someone living with cardiac sarcoidosis. Through her advocacy, including work with FSR's 'Ignore No More' campaign, she has helped raise national awareness about the disease and its disproportionate impact on Black women. Her keynote will offer inspiration, insight, and a deeply personal perspective on the power of community in the face of chronic illness. Interactive community forums, video chats, and a virtual exhibit hall featuring more than 20 educational booths will allow participants to connect, ask questions, and access trusted resources. FSR's Global Sarcoidosis Clinic Alliance members will also be present to offer local and specialized care insights. Registration will close on June 14, 2025. Scholarships are available for those in need of financial assistance. All registrants will receive 30-day access to summit session recordings and resources to view post-event. To register, apply for a scholarship, or learn more, visit: Sarcoidosis Sarcoidosis is a rare inflammatory disease that causes the immune system to form granulomas—clusters of inflammatory cells—in one or more organs. Symptoms can vary widely and may include fatigue, shortness of breath, chronic pain, and neurological issues. Sarcoidosis is difficult to diagnose and currently has no known cure. About the Foundation for Sarcoidosis Research (FSR) The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving patient care through research, education, and support. Since its founding in 2000, FSR has invested over $8 million in sarcoidosis-specific research and built a global community of support. Learn more at Media Contact: Cathi Davis Director of Communications and Marketing 312-341-0500 cathi@ A photo accompanying this announcement is available at
Yahoo
3 days ago
- Yahoo
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
